Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
September 17, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
September 15, 2020 07:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
September 14, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 16:25 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress
September 10, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 08, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting
August 31, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation Initiation of Phase 3, placebo-controlled,...
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
August 28, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
August 20, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...